Cefoxitin

Bacterial Infections

Cefoxitin is prescribed to treat serious infections caused by susceptible bacteria. It is effective against various types of infections, including:

• Lower respiratory tract infections: Such as pneumonia and lung abscesses.
• Urinary tract infections: Infections affecting the bladder or kidneys.
• Intra-abdominal infections: Including peritonitis (inflammation of the stomach lining) and abscesses within the abdomen.
• Gynecological infections: Such as pelvic inflammatory disease, endometritis, and pelvic cellulitis.
• Bloodstream infections: Also known as septicemia.
• Bone and joint infections: Infections that affect the skeletal system.
• Skin and skin structure infections: Including deep tissue infections.

Surgical Prevention

Healthcare providers also use cefoxitin to prevent infections in patients undergoing specific surgical procedures. This is known as prophylaxis. It is commonly used for:

• Gastrointestinal surgeries, such as colorectal procedures.
• Vaginal hysterectomies.
• Cesarean sections.

In these cases, the medication is typically administered shortly before the procedure and may be continued for a brief period afterward to reduce the risk of post-operative infection.

Mechanism of Action

Cefoxitin belongs to a group of medicines called cephalosporin antibiotics. It works by interfering with the way bacteria build their cell walls. These walls are essential for the bacteria to maintain their structure and protect themselves from the surrounding environment.

When bacteria are growing and dividing, they must constantly repair and rebuild their cell walls. Cefoxitin binds to specific proteins within the bacteria, blocking the final steps of cell wall construction. This creates weak spots in the wall, which eventually causes the bacteria to rupture and die.

Targeting Bacteria

Because human cells do not have cell walls, cefoxitin specifically targets the bacteria causing the infection without harming the patient's cells. It is effective against a variety of bacteria, including certain types that can live without oxygen, known as anaerobes.

It is important to note that cefoxitin only works against bacterial infections. It does not kill viruses and is not effective for treating viral illnesses like the common cold or the flu.

Common Side Effects

• Pain, tenderness, or swelling at the injection site
• Diarrhea
• Nausea or vomiting
• Loss of appetite

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of an allergic reaction, such as skin rash, itching, hives, or swelling of the face, lips, tongue, or throat
• Severe stomach pain or watery or bloody diarrhea, which may occur during treatment or several months after the last dose
• Difficulty breathing or swallowing
• Unusual bleeding or bruising
• Yellowing of the skin or eyes
• Decreased urination or changes in urine output
• Seizures
• New signs of infection, such as fever, chills, or sore throat

Allergic Reactions

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibiotics. Before therapy begins, it is important to determine if there is a history of hypersensitivity to cefoxitin, other cephalosporins, or penicillins. There is a risk of cross-sensitivity among these types of medications, and cefoxitin should be used with extreme caution in penicillin-sensitive patients.

Clostridioides difficile-Associated Diarrhea

Nearly all antibacterial agents, including cefoxitin, can cause Clostridioides difficile-associated diarrhea (CDAD). This condition can range in severity from mild diarrhea to life-threatening colitis. Treatment with antibiotics alters the natural bacteria in the colon, which may allow C. difficile to grow. It is important to consider this diagnosis in patients who develop diarrhea during or after treatment.

Kidney Function

Cefoxitin is primarily excreted by the kidneys. In patients with reduced kidney function, the total daily dosage should be adjusted to prevent the accumulation of the drug and potential toxicity. Monitoring of renal function may be appropriate during therapy, especially in severely ill patients receiving maximum doses or those also taking aminoglycoside antibiotics.

Antibiotic Resistance

Using cefoxitin without a confirmed or strongly suspected bacterial infection is unlikely to provide benefit and may increase the risk of developing drug-resistant bacteria. Prolonged use may also result in the overgrowth of nonsusceptible organisms, such as fungi.

Blood Clotting and Monitoring

Some cephalosporins have been associated with a decrease in prothrombin activity, which can affect blood clotting. Patients at higher risk include those with kidney or liver impairment, those with poor nutritional status, and those on prolonged antibiotic therapy. Monitoring of prothrombin time may be necessary for these individuals, and vitamin K may be administered if indicated.

Pregnancy

There are no adequate and well-controlled studies of cefoxitin use in pregnant women. Animal reproduction studies using high doses in rats and mice have not shown evidence of impaired fertility or harm to the fetus. Because animal studies are not always predictive of human response, this medication should be used during pregnancy only if a healthcare provider determines it is clearly necessary.

Breastfeeding

Cefoxitin is excreted in human breast milk in low concentrations. While it is generally considered compatible with breastfeeding, caution is advised. Potential effects on a nursing infant may include:

• Changes in bowel habits, such as diarrhea
• Development of a yeast infection, such as oral thrush or diaper rash
• Allergic reactions

Individuals who are breastfeeding should discuss the potential risks and benefits with their healthcare provider before using this medication.

Available Forms

Cefoxitin is provided in several injectable formats for administration by a healthcare professional:

• Powder for Injection: This form is supplied as a dry powder in vials. It must be reconstituted with a compatible sterile liquid before being administered either intravenously or intramuscularly.
• Premixed Solution: This form is available as a ready-to-use liquid in containers designed for intravenous infusion. These are often stored frozen and must be thawed before use.

This medication is not available in oral forms such as tablets or capsules.

FDA Approval Status

Cefoxitin was initially approved by the U.S. Food and Drug Administration (FDA) in 1978. It is currently available as a generic medication and is typically administered by a healthcare professional via intravenous or intramuscular injection.

Approved Indications

The FDA has approved cefoxitin for the treatment of serious infections caused by susceptible strains of specific bacteria. Approved clinical uses include:

• Lower respiratory tract infections, including pneumonia and lung abscess.
• Urinary tract infections.
• Intra-abdominal infections, such as peritonitis and intra-abdominal abscess.
• Gynecological infections, including pelvic inflammatory disease, endometritis, and pelvic cellulitis.
• Septicemia (bloodstream infections).
• Bone and joint infections.
• Skin and skin structure infections.

Cefoxitin is also indicated for perioperative prophylaxis. It is used to prevent infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated, such as gastrointestinal surgery, vaginal hysterectomy, or cesarean section.

Regulatory Warnings and Safety Communications

There are no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with cefoxitin. However, the FDA-approved labeling includes several important safety considerations:

• Hypersensitivity Reactions: Serious and occasionally fatal allergic reactions (anaphylaxis) have been reported. Healthcare providers are advised to check for a history of cephalosporin or penicillin allergy before administration due to the risk of cross-sensitivity.
• Clostridioides difficile-associated diarrhea (CDAD): Like most antibiotics, cefoxitin can alter the normal flora of the colon, leading to the overgrowth of C. difficile. This can result in diarrhea ranging in severity from mild to fatal colitis.
• Antibiotic Resistance: To prevent the development of drug-resistant bacteria and maintain the effectiveness of the drug, the FDA recommends that cefoxitin be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.